RT journal article T1 Safety and efficacy of convalescent plasma for COVID-19 in the pre-vaccine era, and implementation in a large healthcare system: A phase I/II randomized, multicentre clinical trial (PC-COVID) A1 Caponcello, Maria Giulia A1 Macías Sánchez, Maria del Mar A1 Macías, Juan A1 Aguilar Guisado, Manuela A1 Romero Palacios, Alberto A1 Retamar Gentil, Pilar A1 Márquez-Gómez, Ignacio A1 Martínez-Marcos, Francisco Javier A1 López Cardenas, Salvador A1 Marrugal Lorenzo, Jose Antonio A1 Quijano Ruiz, Blanca A1 Mata, Rosario A1 Carmona Sánchez, Gloria A1 Oyonarte, Salvador A1 Rodríguez Baño, Jesús A2 Cirugía A2 Medicina K1 COVID-19 K1 Convalescent plasma K1 Clinical trial AB Introduction: A phase 2 trial was conducted to evaluate the safety and efficacy of convalescent plasma (CP) for patients admitted with COVID-19 in the pre-vaccine era. Methods: CP was compared to standard of care (SoC) in a randomized clinical trial in patients admitted with COVID-19 pneumonia and with either hypoxia and/or some underlying condition from April to December 2020 in 15 hospitals in Andalusia, Spain. The primary endpoints were adverse events and failure (all-cause death and need for mechanical ventilation during the first 21 days). Result: The procedure for CP was developed and worked properly. Overall, 72 patients of 88 evaluated were recruited (37 and 35) assigned to CP and SoC. Median duration of COVID-19 related symptoms was 7 and 6 days, and median oxygen saturation at randomization was 93% and 92.5% in experimental and control arms, respectively. Overall, 8 (21.6%) patients in the experimental CP group (non related to CP) and 8 (22.9%) in the control group developed grade 3 adverse events (relative risk [RR] 0.94; 95% CI: 0.39–2.24); failure occurred in 3 (8.1%) and 4 (11.4%) patients, respectively ([RR] 0.94, CI: 0.14–6.35 for both events). No differences in secondary endpoints (change in inflammatory parameters, negativization of SARS-CoV-2 PCR or duration of hospital stay) were found. Conclusions: The results suggested that CP is safe for use in COVID-19 patients, although no significant efficacy signal could be observed. A successful regional system for CP administration was developed. PB ELSEVIER SN 1578-1852 YR 2026 FD 2026-03-31 LK http://hdl.handle.net/10498/40626 UL http://hdl.handle.net/10498/40626 LA eng DS Repositorio Institucional de la Universidad de Cádiz RD 19-nov-2026